Product Description
Mechanisms of Action: Unknown
Novel Mechanism: No
Modality: Small Molecule
Route of Administration: Oral
FDA Designation: None *
Approval Status: Not Approved
Approved Countries: None
Approved Indications: None
Known Adverse Events: None
Company: Changzhou Hengbang Pharmaceutical Co., Ltd./Shanghai Hansen Biomedical Technology Co., Ltd./Jiangsu Hansoh Pharmaceutical Group Co., Ltd.
Company Location:
Company CEO:
Additonal Commercial Interests: None
Clinical Description
Countries in Clinic: China
Active Clinical Trial Count: 3
Highest Development Phases
Phase 2: Glomerulonephritis|IgA Nephropathy|Kidney Diseases
Phase 1: Glomerulosclerosis, Focal Segmental
Trial |
Phase |
Trial Status |
Disease |
Primary Completion Date |
Probability of Success |
---|---|---|---|---|---|
HS-10390-201 | P2 |
Not yet recruiting |
Kidney Diseases|Glomerulonephritis|IgA Nephropathy |
2025-12-01 |
|
HS-10390-101 | P1 |
Recruiting |
IgA Nephropathy|Glomerulosclerosis, Focal Segmental|Glomerulonephritis |
2024-02-16 |
|
CTR20230998 | P1 |
Not yet recruiting |
Glomerulosclerosis, Focal Segmental|IgA Nephropathy |
None |